Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

457.80 +9.18 (+2.05%)

Streaming Delayed Price Updated: 3:17 PM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

72 73 Next >

Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis

February 05, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Stocks Fall As Traders Dial Back Rate Cut Bets; Dollar, Treasury Yields Rise: What's Driving Markets Monday? ↗

February 05, 2024

Wall Street ends week on negative note as traders revise down expectations on Fed rate cuts. Strong economic data and Fed officials' comments push stocks into red, reducing rate cut expectations for...

Via Benzinga

Topics Economy

Earnings Preview: Vertex Pharmaceuticals ↗

February 02, 2024

Via Benzinga

Key Takeaways From Vertex Pharmaceuticals Analyst Ratings ↗

January 31, 2024

Via Benzinga

Here's My Top Growth Stock to Buy Right Now ↗

January 27, 2024

There doesn't appear to be a weak link with this great stock.

Via The Motley Fool

Vertex Pharmaceuticals Gears Up For Q4 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗

February 05, 2024

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is expected to release earnings results for its fourth quarter, after the closing bell on Feb. 5, 2024.

Via Benzinga

Will Jerome Powell Spoil Wall Street's Party? US Stock Futures Slip As Fed Chief Maintains Hawkish Tone Ahead Of More Earnings ↗

February 05, 2024

As the market pushes higher despite the Federal Reserve's non-committal stance, traders fear a potential drawdown.

Via Benzinga

Topics Economy

Investor Optimism Improves Following Tech Earnings, Jobs Data; S&P 500 Gains For 4th Week ↗

February 05, 2024

The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, while the index remained in the "Greed" zone on Friday. U.S. stocks closed higher on Friday, with the S&P 500...

Via Benzinga

Topics Stocks

Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 3 ↗

February 03, 2024

What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the week of Jan. 29 through Feb. 2.

Via Talk Markets

Where Will Vertex Pharmaceuticals Be in 10 Years? ↗

January 25, 2024

As the adage goes, winners keep winning.

Via The Motley Fool

Earnings Scheduled For February 5, 2024 ↗

February 05, 2024

Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is estimated to report quarterly earnings at $0.26 per share on revenue of $43.92 million.

Via Benzinga

Vertex Pharmaceuticals May Be About to Solve a Common Health Problem. Is the Stock a Buy? ↗

February 02, 2024

Vertex shares recently reached an all-time high.

Via The Motley Fool

Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review ↗

February 02, 2024

The Dow led the major indexes higher. Big techs diverged on results.

Via Investor's Business Daily

Topics Economy Stocks

Should Quality Investors Include NASDAQ:VRTX in Their Portfolio? ↗

February 02, 2024

In this article we'll explore the quality characteristics of VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX)

Via Chartmill

Top Stock Picks 2024: 3 Healthcare Stocks Leading Medical Advancements ↗

February 01, 2024

Discover how emerging tech is shaping healthcare stocks in 2024. See which companies are outperforming and what it means for your portfolio.

Via InvestorPlace

Biotech And Medtech Portfolio Notes On A Fed Day ↗

January 31, 2024

The Fed held rates keeping their future options flexible with no expectations for future cuts. The market did not like it and sold off with the Russell 2000 down 2.45% and the NASDAQ down 2.23%

Via Talk Markets

Topics Economy

Buy Alert: 3 Stocks Sitting in the Sweet Spot ↗

January 31, 2024

They say timing is everything, so investors will want to take advantage of buying these stocks now instead of waiting.

Via InvestorPlace

Why Vertex Pharmaceuticals Stock Topped the Market Today ↗

January 30, 2024

The company reported that it met its primary endpoint in a study for its non-opioid pain drug.

Via The Motley Fool

Why Is Vertex Pharmaceuticals Stock Sliding Today? ↗

January 30, 2024

Explore Vertex Pharmaceuticals' Phase 3 results for VX-548, a NaV1.8 inhibitor, demonstrating significant pain relief post-surgery.

Via Benzinga

Vertex Skids — Its Alternative To Opioids Is 'Not A Game-Changer,' Says Analyst ↗

January 30, 2024

The company unveiled the results of Phase 3 testing in patients following a tummy tuck or bunion removal.

Via Investor's Business Daily

Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain

January 30, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Is CRISPR Therapeutics a Buy in the New Bull Market? ↗

January 30, 2024

CRISPR Therapeutics is a specialist in the hot technology of gene editing.

Via The Motley Fool

AI, Biotech, Energy Sectors Expect M&A Revival For 2024 ↗

January 29, 2024

The AI market, along with energy and biotech, are ripe for M&A following the worst performance in almost a decade for deal-making in 2023.

Via Benzinga

Topics Artificial Intelligence

3 Magnificent Stocks to Buy and Hold Forever ↗

January 27, 2024

Many investors will want to consider owning these stocks for a long time.

Via The Motley Fool

Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals? ↗

January 25, 2024

It's always tough to be compared to a giant.

Via The Motley Fool

Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January ↗

January 25, 2024

These biotech stocks offer exciting and disruptive solutions with the potential to expand to market caps worth trillions.

Via InvestorPlace

Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts ↗

January 24, 2024

UBS insights on Biogen Inc's challenges with Leqembi in the Alzheimer's market. Analyst downgrades, revised sales estimates, and CEO's growth strategy.

Via Benzinga

Where Will CRISPR Therapeutics Be in 5 Years? ↗

January 24, 2024

The company could maintain the momentum it gained last year.

Via The Motley Fool

Netflix To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

January 24, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

2 Super Stocks You'll Wish 5 Years From Now That You'd Bought Today ↗

January 24, 2024

These powerhouse stocks still have plenty of growth catalysts to tap into over the coming years.

Via The Motley Fool

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

72 73 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.